Nitorum Capital buys $13,552,607 stake in Haemonetics Corporation (HAE)

Haemonetics Corporation (HAE) : Nitorum Capital scooped up 56,911 additional shares in Haemonetics Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 351,833 shares of Haemonetics Corporation which is valued at $13,552,607.Haemonetics Corporation makes up approximately 5.43% of Nitorum Capital’s portfolio.

Other Hedge Funds, Including , Vanguard Group Inc boosted its stake in HAE in the latest quarter, The investment management firm added 157,352 additional shares and now holds a total of 4,194,443 shares of Haemonetics Corporation which is valued at $161,569,944. Haemonetics Corporation makes up approx 0.01% of Vanguard Group Inc’s portfolio.Geode Capital Management boosted its stake in HAE in the latest quarter, The investment management firm added 14,115 additional shares and now holds a total of 352,486 shares of Haemonetics Corporation which is valued at $13,584,810. Haemonetics Corporation makes up approx 0.01% of Geode Capital Management’s portfolio. Tower Research Capital (trc) added HAE to its portfolio by purchasing 4,574 company shares during the most recent quarter which is valued at $168,506. Haemonetics Corporation makes up approx 0.02% of Tower Research Capital (trc)’s portfolio.Neuberger Berman Group reduced its stake in HAE by selling 42,095 shares or 2.19% in the most recent quarter. The Hedge Fund company now holds 1,881,814 shares of HAE which is valued at $62,306,862. Haemonetics Corporation makes up approx 0.09% of Neuberger Berman Group’s portfolio.

Haemonetics Corporation closed down -0.33 points or -0.84% at $38.95 with 3,69,411 shares getting traded on Monday. Post opening the session at $39.42, the shares hit an intraday low of $38.85 and an intraday high of $39.71 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Haemonetics Corporation reported $0.38 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Nov 7, 2016. Analyst had a consensus of $0.35. The company had revenue of $220.30 million for the quarter, compared to analysts expectations of $210.78 million. The company’s revenue was up .3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.44 EPS.

Many Wall Street Analysts have commented on Haemonetics Corporation. Company shares were Reiterated by The Benchmark Company on Nov 7, 2016 to “Hold”, Firm has raised the Price Target to $ 34 from a previous price target of $32 .Haemonetics Corporation was Downgraded by CJS Securities to ” Market Perform” on Sep 20, 2016.

Haemonetics Corporation is a healthcare company which provides blood management solutions to its customers. The Company’s portfolio of integrated devices information management and consulting services offers blood management solutions for each facet of the blood supply chain. It serves three customer segments: manufacturers of plasma derived pharmaceuticals blood collectors and hospitals. Its multiple product lines under four global product categories include Plasma Blood Center Hospital and Software Solutions. Its Plasma includes plasma collection devices and disposables. Its Blood Center includes blood collection and processing devices and disposables. Its Hospital includes surgical blood salvage and blood demand diagnostic devices and disposables. Its Software Solutions includes information technology platforms and consulting services provided to all three markets. It operates in North America Plasma North America Blood Center and Hospital Europe Asia Pacific and Japan.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Haemonetics Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Haemonetics Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.